The value of full-length transcripts without bias

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

whitePaper | November 18, 2022

It’s the same for manufacturers across industries and across the globe; there’s a steadily increasing pressure to meet market demand, despite facing new challenges andconstraints.

whitePaper | December 5, 2022

Serialisation has emerged as a complex challenge for the pharmaceuticals sector which is facing a multiplicity of differing regulations that vary from one country to another.

whitePaper | January 21, 2023

Emerging Diseases Require New Tools Medicines to treat and prevent infectious diseases cover a broad range of modalities from dosed therapeutics to vaccines. Biotherapeutics require a detailed knowledge of binding sites, or epitopes, on their respective antigens.

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.